IMUX, US4525EP2001

Immunic stock fell 7.87 percent before Phase 3 results rollout

Published on 10/05/2026 at 13:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immunic stock was last at USD 7.96 on October 2, 2026, after a 7.87 percent decline. Cash of USD 155.1 million supports trials into late 2027.

IMUX, US4525EP2001, Illustration mit AI erstellt.

Immunic (US4525EP2001) stock was last at USD 7.96 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 7.87 percent from the prior session. The company is advancing Phase 3 multiple sclerosis trials toward top-line data expected by the end of 2026, according to Immunic in its August 11, 2026 update.

Second-quarter loss widens

Immunic reported USD 35.3 million in operating expenses and a USD 34.1 million net loss for the second quarter ended June 30, 2026. The GAAP loss was USD 0.80 per diluted share, compared with USD 2.03 per diluted share in the second quarter of 2025, while the share count rose to 42.5 million from 13.2 million.

Research and development spending reached USD 25.9 million in the second quarter, up from USD 21.3 million a year earlier, as the company funded drug interaction studies and preparation for a potential regulatory filing. General and administrative expenses were USD 9.4 million, compared with USD 5.7 million in the prior-year quarter, according to Immunic.

Cash funds the clinical timetable

Cash and cash equivalents stood at USD 155.1 million on June 30, 2026, and management said the balance should fund operations into late 2027, according to Immunic. That runway gives the stock a clear clinical timetable, but the investment case still depends on results from the ENSURE-1 and ENSURE-2 trials and later regulatory execution.

The company also plans to initiate a Phase 3 program in progressive multiple sclerosis later in 2026. Its lead candidate, vidofludimus calcium, combines Nurr1 activation with selective DHODH inhibition, a development strategy described by Immunic as the basis for its multiple sclerosis program.

Analysts keep bullish targets

On September 10, 2026, Wedbush reiterated a Buy rating and a USD 45.00 price target, while LifeSci Capital maintained a Buy rating and a USD 56.00 target on September 1, 2026, as reported by Markets Insider.

A separate consensus compiled by Rallies on October 2, 2026 showed a Strong Buy rating from nine analysts, with an average price target of USD 39.14. That target lies 391.7 percent above the USD 7.96 reference price, making the clinical readouts the central test of whether the market can support those expectations.

Stock stays below yearly high

IMUX was last at USD 7.96 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with volume of 723,262 shares and market capitalization of USD 108.4 million; the price stood 54.3 percent below its 52-week high of USD 17.43.